Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
about
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activationFrom chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.Myelodysplasia in younger adults: outlier or unique molecular entity?
P2860
Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Thrombocytopenia in MDS: epide ...... novel therapeutic strategies.
@ast
Thrombocytopenia in MDS: epide ...... novel therapeutic strategies.
@en
type
label
Thrombocytopenia in MDS: epide ...... novel therapeutic strategies.
@ast
Thrombocytopenia in MDS: epide ...... novel therapeutic strategies.
@en
prefLabel
Thrombocytopenia in MDS: epide ...... novel therapeutic strategies.
@ast
Thrombocytopenia in MDS: epide ...... novel therapeutic strategies.
@en
P2093
P2860
P356
P1433
P1476
Thrombocytopenia in MDS: epide ...... novel therapeutic strategies.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2015.297
P50
P577
2015-10-26T00:00:00Z
P6179
1004305329